Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

17.69 -0.03 (-0.17%)
Streaming Delayed Price Updated: 9:43 AM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 66,172
Open 17.62
Bid (Size) 17.64 (200)
Ask (Size) 17.70 (200)
Prev. Close 17.72
Today's Range 17.48 - 17.72
52wk Range 16.10 - 30.48
Shares Outstanding 116,457,008
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-31.6%
-31.6%
1 Month
-21.3%
-21.3%
3 Month
-29.7%
-29.7%
6 Month
-22.3%
-22.3%
1 Year
-25.5%
-25.5%

More News

Read More
News headline image
Apellis (APLS) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Apellis Pharmaceuticals Inc (NASDAQ:APLS) Reports Q4 2025 Earnings Beat Amid Mixed Revenue Results ↗
Via Chartmill
Topics Earnings
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Pairs Strong Growth with Bullish Chart Setup ↗
Via Chartmill
Apellis Pharmaceuticals (NASDAQ:APLS) Fits the 'Affordable Growth' Investment Strategy ↗
Via Chartmill
News headline image
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Presents a Compelling Growth and Technical Breakout Setup ↗
Via Chartmill
News headline image
Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals Inc (NASDAQ:APLS) Fits the 'Growth at a Reasonable Price' Strategy ↗
Via Chartmill
News headline image
Arteris Fortifies AI-Driven Future with Strategic Acquisition of Cycuity, Championing Semiconductor Cybersecurity
Via TokenRing AI
Topics Artificial Intelligence Economy Intellectual Property
News headline image
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Emerges as a Prime GARP Investment ↗
Via Chartmill
News headline image
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Presents an Affordable Growth Opportunity ↗
Via Chartmill
News headline image
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power ↗
Via Benzinga
News headline image
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
Via Benzinga
News headline image
Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Here are the top movers in Thursday's session. ↗
Via Chartmill

Frequently Asked Questions

Is Apellis Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Apellis Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Apellis Pharmaceuticals, Inc. - Common Stock trade on?
Apellis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock is APLS on the Nasdaq Stock Market
What is the current price of Apellis Pharmaceuticals, Inc. - Common Stock?
The current price of Apellis Pharmaceuticals, Inc. - Common Stock is 17.69
When was Apellis Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Apellis Pharmaceuticals, Inc. - Common Stock was at 03/26/26 09:43 AM ET
What is the market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock is 2.06B
How many shares of Apellis Pharmaceuticals, Inc. - Common Stock are outstanding?
Apellis Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.